Is Comparative Effectiveness Antithetical to Personalized Medicine?
This article was originally published in RPM Report
Executive Summary
Critics of comparative clinical effectiveness argue that the research, which relies in part on large-scale clinical trials, directly conflicts with personalized medicine's focus on patient sub-populations. Can the two peacefully co-exist?
You may also be interested in...
Comparative Effectiveness: The Next Gatekeeper to Commercial Success
The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?
Comparative Effectiveness: The Next Gatekeeper to Commercial Success
The hot new buzzword with policymakers is comparative clinical effectiveness, and everyone has an idea on how to make it work. But major questions remain: what might a national effort look like? And will payors use it to restrict access to new drugs?
Getting Personal: FDA's Plan to Save the Drug Industry
There's no question the pharmaceutical industry is desperate for a more efficient R&D machine, and FDA thinks it has one answer: personalized medicine. But for Big Pharma, the idea runs counter to the commercial reality: no one has yet demonstrated a viable model for making personalized medicine pay off. Knowing where and how to invest in personalized medicine--and taking advantage of FDA's interest the area--will increase the chances of commercial success.